Residency · Residency · Chronic Pain Management
Chronic Pain in the Elderly
Introduction
Chronic pain affects 25-50% of community-dwelling older adults and up to 80% of nursing home residents, yet it remains systematically undertreated in this population. Age-related changes in pharmacokinetics and pharmacodynamics, cognitive impairment, polypharmacy, and fall risk create unique challenges that demand modified assessment and treatment strategies. Effective pain management in the elderly requires balancing analgesic efficacy against the heightened vulnerability to adverse drug events.
Age-Related Pharmacokinetic Changes
Absorption
Reduced gastric acid secretion and slower gastric emptying delay but rarely reduce total drug absorption. Decreased first-pass metabolism due to reduced hepatic blood flow increases the bioavailability of high-extraction drugs such as morphine and fentanyl. Transdermal absorption may be altered by decreased skin hydration and changes in subcutaneous fat.
Distribution
Increased body fat percentage (a 20-40% increase with aging) expands the volume of distribution for lipophilic drugs like fentanyl and diazepam, prolonging their half-life. Decreased total body water (a 10-15% reduction) concentrates hydrophilic drugs such as morphine and gabapentin. Reduced serum albumin increases the free fraction of protein-bound drugs like naproxen and warfarin, amplifying both their efficacy and their toxicity.
Metabolism
Hepatic mass decreases by 25-35% and hepatic blood flow by 40% between ages 25 and 65. Phase I reactions (oxidation via CYP450) are more significantly impaired than Phase II reactions (conjugation). Drugs relying on CYP3A4 and CYP2D6 metabolism require dose adjustment. Genetic polymorphisms in CYP2D6 that affect opioid metabolism are additive with age-related metabolic decline.
Excretion
Glomerular filtration rate declines approximately 1 mL/min/year after age 40. Creatinine clearance is the most clinically relevant parameter; serum creatinine alone is misleading because reduced muscle mass can mask true renal impairment. The Cockcroft-Gault or CKD-EPI equations should guide renal dose adjustments. Accumulation of active metabolites -- morphine-6-glucuronide and gabapentin being the most clinically relevant -- poses significant risk in elderly patients with declining renal function.
<image>Anatomical illustration showing age-related pharmacokinetic changes in an elderly patient, with labeled callouts pointing to the liver (reduced mass and blood flow, decreased Phase I metabolism), kidneys (reduced GFR, impaired drug clearance), body composition (increased adipose tissue expanding lipophilic drug distribution, decreased lean mass and total body water concentrating hydrophilic drugs), and GI tract (reduced gastric acid, slower motility), with arrows indicating how each change affects drug levels and clinical dosing implications.</image>
Beers Criteria and Medications to Avoid
The American Geriatrics Society (AGS) Beers Criteria identifies potentially inappropriate medications in older adults. Several entries are directly relevant to pain management.
| Beers Category | Medication | Reason to Avoid/Caution | Alternative |
|---|---|---|---|
| Avoid | Meperidine | Neurotoxic metabolite (normeperidine); seizure risk | Morphine, hydromorphone (dose-adjusted) |
| Avoid | Indomethacin | Highest CNS adverse effects among NSAIDs | Topical NSAIDs; short-course naproxen |
| Avoid | Muscle relaxants (cyclobenzaprine, carisoprodol) | Anticholinergic burden; sedation; falls | Physical therapy; topical agents |
| Avoid | Benzodiazepines | Fall risk; cognitive impairment; paradoxical agitation | Duloxetine for pain-anxiety; CBT |
| Caution | All NSAIDs | 4x GI bleeding risk; renal/CV toxicity | Topical NSAIDs; acetaminophen; duloxetine |
| Caution | Tramadol | Seizure risk; serotonin syndrome; variable CYP2D6 metabolism | Low-dose strong opioid with monitoring |
| Caution | Gabapentin/pregabalin | Sedation; falls (start at 50% adult dose) | Low-dose with slow titration |
| Caution | TCAs (amitriptyline) | Anticholinergic; cardiac conduction; orthostasis | Nortriptyline preferred if TCA needed |
Strong Avoid Recommendations
Meperidine should be avoided because its neurotoxic metabolite normeperidine accumulates and carries seizure risk. Indomethacin has the highest CNS adverse effect profile among NSAIDs. Skeletal muscle relaxants -- cyclobenzaprine, methocarbamol, carisoprodol -- carry anticholinergic burden and sedation with limited efficacy. Benzodiazepines increase fall risk and cognitive impairment and can cause paradoxical agitation; they should be avoided for chronic pain-related anxiety. Long-acting opioids should not be used as first-line therapy without a prior trial of short-acting agents.
Use with Caution
All NSAIDs carry a 4-fold increased GI bleeding risk in patients over 65, along with renal and cardiovascular toxicity; they should be limited to the shortest duration at the lowest effective dose. Tramadol carries seizure risk and serotonin syndrome potential, with unpredictable CYP2D6-dependent metabolism. Gabapentin and pregabalin produce dose-dependent sedation and fall risk; starting doses should be 50% of adult doses. Tricyclic antidepressants have anticholinergic effects, cardiac conduction abnormalities, and cause orthostatic hypotension; nortriptyline is preferred over amitriptyline if a tricyclic must be used.
Fall Risk Considerations
Falls are the leading cause of injury-related death in adults over 65. Opioids increase fall risk by 40-60% in a dose-dependent fashion. Gabapentinoids increase fall risk by 30-40%, particularly during dose titration. Concomitant use of opioids, benzodiazepines, and gabapentinoids creates multiplicative fall risk. Pre-treatment fall risk assessment using the Timed Up and Go test or Berg Balance Scale should be documented. Environmental modifications and physical therapy for balance training are essential adjuncts to any pharmacologic pain management strategy.
Cognitive Impairment and Pain Assessment
Challenges
Patients with moderate-to-severe dementia cannot reliably self-report pain using standard scales. Pain in these patients is frequently misattributed to behavioral disturbance and treated with antipsychotics rather than analgesics. Studies consistently show that cognitively impaired patients receive significantly fewer analgesics than cognitively intact peers with comparable painful conditions.
Assessment Tools for Cognitively Impaired Patients
Several observational scales are available. The PAINAD (Pain Assessment in Advanced Dementia) scale assesses breathing patterns, vocalization, facial expression, body language, and consolability. The Abbey Pain Scale is a six-item observational tool validated in nursing home populations. The FLACC Scale, originally developed for pediatric patients, is increasingly used in nonverbal adults. Behavioral indicators to watch for include grimacing, guarding, agitation, resistance to care, vocalization, and changes in activity patterns. When behavioral changes suggest unrecognized pain, empiric analgesic trials should be considered.
<image>Side-by-side comparison of pain assessment approaches in elderly patients, showing on the left a cognitively intact elderly patient using a numeric rating scale and verbal descriptor scale, and on the right a cognitively impaired patient being assessed using observational tools (PAINAD scale) with labeled behavioral indicators including facial grimacing, body guarding, vocalization patterns, breathing changes, and resistance to care, with scoring rubrics shown below each approach.</image>
Modified Interventional Approaches
Considerations for Procedures in the Elderly
Interventional pain procedures in elderly patients require several special considerations. High prevalence of anticoagulation with warfarin, DOACs, and antiplatelet agents necessitates bridging protocols. Osteoporotic bone changes alter fluoroscopic landmarks and needle trajectories. Spinal stenosis may limit epidural access, and interlaminar approaches may be preferred over transforaminal in severe stenosis. Sedation for procedures carries higher risk, so minimal sedation or local anesthesia-only protocols should be considered. Infection risk is elevated due to immunosenescence, making strict aseptic technique paramount.
Preferred Interventional Strategies
Intra-articular corticosteroid injections are useful for osteoarthritis flares, though frequency should be limited due to potential cartilage effects. Genicular nerve radiofrequency ablation for knee osteoarthritis offers an alternative to total knee arthroplasty in patients who are poor surgical candidates. Vertebral augmentation (kyphoplasty or vertebroplasty) addresses acute osteoporotic compression fractures. Peripheral nerve blocks provide localized pain relief with a favorable safety profile. Intrathecal drug delivery is an option for refractory cancer or non-cancer pain when systemic medications cause intolerable side effects.
Polypharmacy Management
The average older adult with chronic pain takes 7-12 medications, creating substantial drug interaction risk. Medication reconciliation at every visit is essential. Deprescribing frameworks such as the Bruyere/STOPP-START criteria help identify medications eligible for discontinuation. Pharmacist-led medication review reduces adverse drug events by 20-30%. Scheduled analgesic regimens are preferable to PRN dosing, because cognitively impaired patients may not request medications even when in pain. The guiding principle is "start low, go slow, but go" -- underdosing is as problematic as overdosing in pain management.
<image>Infographic depicting a polypharmacy management strategy for elderly chronic pain patients, showing a medication timeline with icons representing common drug classes (antihypertensives, anticoagulants, analgesics, antidepressants, gabapentinoids, PPIs), with red warning symbols at known drug-drug interaction points, green checkmarks for appropriate combinations, and a decision tree for deprescribing steps including tapering protocols, monitoring parameters, and functional outcome reassessment.</image>
Non-Pharmacological Approaches
Exercise therapy remains the most evidence-based intervention for pain in the elderly. Tai chi, aquatic therapy, and chair-based exercise programs improve function and reduce falls. Transcutaneous electrical nerve stimulation (TENS) provides safe analgesia without systemic effects. Cognitive-behavioral therapy can be adapted for older adults with or without cognitive impairment. Heat and cold therapy are effective for musculoskeletal conditions. Massage and manual therapy are beneficial but require attention to osteoporotic fracture risk. Social engagement and meaningful activity reduce pain perception and suffering -- isolation amplifies pain, and connection attenuates it.
Clinical Pearls
"Start low, go slow, but don't stop too low": inadequate pain treatment in the elderly leads to depression, deconditioning, falls from pain-related gait instability, and reduced quality of life. Acetaminophen scheduled at 1,000 mg three times daily (maximum 2 g/day in the frail elderly) is the safest first-line systemic analgesic. Topical agents -- diclofenac gel, lidocaine patches, capsaicin -- provide local analgesia with minimal systemic absorption and should be used early in the treatment algorithm. Always check eGFR before prescribing NSAIDs, gabapentin, or pregabalin, and reassess renal function periodically. Behavioral changes in dementia patients should trigger a structured pain assessment before escalating psychotropic medications.
References
- Abdulla A, Adams N, Bone M, et al. Guidance on the management of pain in older people. Age and Ageing. 2013;42(Suppl 1):i1-i57.
- American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. Journal of the American Geriatrics Society. 2009;57(8):1331-1346.
- By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria. Journal of the American Geriatrics Society. 2023;71(7):2052-2077.
- Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. Journal of the American Medical Directors Association. 2003;4(1):9-15.
